Your search for bevacizumab returned 2 results

The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.

Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.